Olink enters into an agreement with deCODE genetics for early access to the Olink Explore 3072 Platform

Olink enters into an agreement with deCODE genetics for early access to the Olink Explore 3072 Platform

UPPSALA, Sweden , July 13, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that deCODE genetics, a global leader in analyzing and understanding the human genome, will have internal access to the Olink® Explore 3072 platform, comprised of approximately 3,000 high quality protein assays with a Next Generation Sequencing (NGS) read-out.

Through an agreement between the two companies, deCODE genetics will be one of the first companies to adopt and internalize the new Explore 3072 proteomics platform and will act as an early testing site for its use. In doing so, deCODE and Olink will work together to optimize Olink’s high throughput, high-quality proteomics to its population scale efforts of advancing modern healthcare.

“We are proud to work closely with deCODE genetics’ world-class genomic and pharmaceutical scientists”, said Jon Heimer, CEO of Olink. “They have a very impressive track record of providing insights to enhance the vital research into the most common and life-threatening diseases. We believe this agreement demonstrates the accelerating trend to continue to connect the wealth of available genomic data with actionable proteomics. We see deCODE genetics as an exceptional early-access site for the Olink Explore 3072 platform.”

Based in Reykjavik, Iceland, deCODE genetics is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE genetics has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer. The purpose of understanding the genetics of disease is to use that information to create new means of diagnosing, treating and preventing disease.

Olink intends to make the Olink Explore 3072 high quality protein assay platform broadly available in the fourth quarter of 2021.

“We believe our carefully curated and validated library of assays, based on our proprietary and patented PEA technology, has the foundation necessary for broad application in large scale discovery as well as more targeted clinical trials and diagnostic applications. We intend to enable our customers to make faster, better-informed scientific decisions by providing this scalable platform for quantification of protein biomarkers in a high-multiplex and high-throughput format. And, of the utmost importance, with assay performance that does not compromise on data quality. We share our customers´ excitement about the expansion of our protein biomarker targets and about making it available to more users around the world through our reagent kits”, says Jon Heimer.

For more information, please contact:
CEO Jon Heimer, Email: jon.heimer@olink.com

About Olink

Olink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden. For more information, please visit www.olink.com.

Forward-Looking Statements

This release may contain forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Olink’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to Olink’s business and operations, strategy, goals and anticipated timelines, including the goal of making Olink Explore 3072 broadly available by the fourth quarter of 2021, and other risks identified in the section entitled “Risk Factors” in Olink’s Registration Statement on Form F-1, as amended (File No. 333-257842) filed with the U.S. Securities and Exchange Commission (SEC) and in the other filings, reports, and documents Olink files with the SEC from time to time. Olink expressly disclaims any obligation to update any forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.